Biotech
Grin Therapeutics
Grin Therapeutics raises $140M Series D at $700M valuation
$140M
Total Raised
Series D
Latest Round
2018
Founded
90+
Employees
New York, NY
1 min read
Quick Facts
Valuation
$700M
Latest Round Size
$140M
Latest Round Date
May 2024
Grin Therapeutics: Series D Funding Round
Grin Therapeutics has successfully raised $140M in Series D funding, reaching a valuation of $700M.
Company Overview
Developer of therapies treating serious neurodevelopmental disorders
Funding Details
The Series D round was led by Fidelity, with participation from Viking Global.
Company Information
- Headquarters: New York, NY
- Founded: 2018
- Employees: 90+
- Category: Biotech
Investment
Grin Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- Fidelity: Verified investor in Series D
- Viking Global: Verified investor in Series D
Key Investors
Fidelity
Lead Investor
Verified investor in Series D
Viking Global
Investor
Verified investor in Series D
About the Author
Editorial Team
Curated funding news from verified sources
Related Company Reports
Biotech
Orna Therapeutics
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Emma Rodriguez
Oct 23, 2025
0 min read•$251M Series B
Biotech
Forge Biologics
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Sarah Kim
Oct 23, 2025
0 min read•$120M Series C
Biotech
Vir Biotechnology
Vir Biotechnology Raises $250M
Clinical-stage immunology company developing treatments for infectious diseases including COVID-19, hepatitis B, and influenza
Sarah Kim
Oct 23, 2025
0 min read•$250M